Carduso Capital invests in start-up Notoxins that develops an innovative remedy for excessive sweating.
Excessive sweating, called hyperhydrosis, is a condition that often has no underlying cause. People who suffer from it experience social consequences in particular. Wet sweat stains and unpleasant odours can contribute to isolation and significantly affect personal confidence.
Based on their own dermatological research, Asser Dermatologist Wim Venema and Apotheker Ben Homan have found an active substance that penetrates deep into the skin and can act directly on the sweat glands. The initial results of the study are so promising that it was subsequently decided to set up the company Notoxins and to seek financing for further development into a (eventually) registered medicine. To date, hardly any suitable medication is available to properly treat hyperhydrosis.
Experienced (clinical) pharmacologist Reinier Schwietert has been recruited to provide the so-called clinical proof of concept for the medicinal use of the found product, who will design and supervise the further test program.
With the investment of Carduso Capital, Notoxins can carry out further developments and carry out the clinical tests, which should make the agent suitable for registered development as a registered pharmacotherapeutic treatment in mid-2022.
For more information please contact:
Notoxins: Reinier Schwietert, (+31) 6-5114 8308 Email: email@example.com
Carduso Capital: Koos Koops, (+31) 6-2298 9098 Email: firstname.lastname@example.org